Nascent Biotech Retires Liabilities with Non-Dilutive Funding

/in , /by

Vero Beach FL, August 10, 2016 – Nascent Biotech, Inc., (“Nascent” or “the Company”) (BB: NBIO) is pleased to announce that through the non-dilutive funding recently received, it has paid nearly $1.7 million in payables and debt, plus created positive shareholders equity.

“With this funding we are now able to advance our asset through accelerated filing of our IND by the end of the year,” said Company CFO Lowell Holden. He further stated, “We have now retired all corporate long-term debt and are in a much better position to not only initiate human clinical trials for Pritumumab, a proprietary monoclonal antibody treatment for brain cancer, but also to ultimately expand from brain cancer into other un-met needs in cancer treatment.”

 

About Nascent Biotech Inc.:

NBI is a biotechnology company developing human Monoclonal Antibodies (mAb’s) for immunotherapy of cancer. Its lead therapeutic candidate, Pritumumab, was the first human antibody ever developed to treat a cancer patient. The company is now developing a new clinical protocol and Initial New Drug (IND) package for commencement of new clinical trials to be conducted in the United States under the guidance of the US Food and Drug Administration (FDA).

 

Safe Harbor:

This news release contains “forward-looking statements” as that term is defined in the United States Securities Act of 1933, as amended and the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements, including beliefs, plans, expectations or intentions regarding the future, and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors, such as the inherent uncertainties associated with new business opportunities and development stage companies. We assume no obligation to update the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that they will prove to be accurate.

 

Contact:

Nascent Biotech Inc

Lowell Holden, CFO

Phone: (612) 961-5656

Fax: (612) 486-7055

Web: www.nascentbiotech.com

Email: lowell.holden@nascentbiotech.com

Nascent Biotech and Hisun Announce an Exclusive License Agreement for the Development and Commercialization of Nascent’s Primary Asset, Pritumumab, in Mainland China

/in , /by

Development planned for multiple Epithelial Cancer Types, starting with brain cancer, in Mainland China.

July 18, 2016 10:00 am EDT

Dateline: TAIZHOU, Zhejiang Province, China & Vero Beach, FL, USA

Public Company Information: OTC: NBIO

Taizhou, Zhejiang Province, China & Vero Beach, FL USA.- Nascent Biotech, Inc. (OTC: NBIO), and Zhejiang Hisun Pharmaceutical Company Ltd., today announced they have entered into an exclusive licensing agreement for the development and commercialization of Nascent’s primary asset, Pritumumab, a monoclonal antibody for the treatment of epithelial cancers (which include brain, pancreas, colon, lung and breast), in mainland China. The agreement between the two companies licenses development, manufacture and commercialization rights for Pritumumab to Hisun, for the treatment of epithelial cancers in China.

“There are significant unmet medical needs in a variety of cancers,” said Sean Carrick, President of Nascent Biotech. “Nascent is committed to changing patient expectations in some of the world’s most debilitating cancers, and licensing Pritumumab to Hisun for therapeutic use in China will bring this promising treatment to significantly more patients who are in need. We’re highly encouraged by the potential of Pritumumab to deliver an innovative, first-in-class treatment option, and we are delighted to be working closely with Hisun in this collaboration.”

Mr. Bai Hua, Chairman of Hisun, expressed that licensing this promising biotech asset will enable Hisun to significantly move forward its goal of diversifying its product portfolio with branded and generic products and achieving Hisun’s long-term vision of “becoming a widely respected international pharmaceutical company” by “persisting in pharmaceutical innovation for the benefit of human beings.”

Under the terms of the agreement, Nascent Biotech will provide to Hisun its Master Cell Bank and related technology, which will allow Hisun to quickly begin manufacturing and further clinical development of Pritumumab in China.

“We are confident that this license agreement will allow Hisun to rapidly fill an unmet need in the cancer space while enabling Nascent to continue to advance this valuable asset in the US. Both companies will benefit greatly from this License arrangement,” added Dr. Haibin Wang, Senior Vice President, Head of Hisun Biopharmaceutical.

About Zhejiang Hisun Pharmaceuticals

With Revenues over $2 Billion annually, Hisun was founded in 1956, the vision of Zhejiang HISUN Pharmaceuticals Co., Ltd. (stock code 600267 – hereinafter called “HISUN”) is to become “a widely respected international pharmaceutical company” by advancing its mission of “persisting in pharmaceutical innovation for the benefit of human beings.” It focuses on the integration of pharmaceutical research and development (R&D) with production resources in order to provide its global customers with outstanding products and services. Visit http://www.hisunpharm.com/.

 

About Nascent Biotech Inc

Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.

Safe Harbor:

 

Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Nascent Biotech, Inc. Announces 2 Additions to Scientific Advisory Board

/in , , /by

San Diego, CA June 17, 2014 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO), announces announced that it has added two internationally renowned cancer experts to its scientific advisory board:

Dr. Santosh Kesari is the director of the Neuro-Oncology Program, director of the Neurotoxicity Treatment Center, director of the Translational Neuro-Oncology Laboratories at Moores Cancer Center and a Professor of Neurosciences at the University Of California San Diego School Of Medicine. Dr. Kesari will be the Principal Clinical Investigator in charge of the Phase I/II human clinical trials in brain cancer for its lead therapeutic monoclonal antibody product Pritumumab.

Dr. Eric F. Glassy is Board certified in Anatomic and Clinical Pathology with a specific interest in Hematopathology, Information Pathology and Digital Pathology as well as being the Medical Director at Pathology Inc. Dr. Glassy is a world recognized Pathologist who has served in several leadership positions in the College of American Pathologists and is a past board member of the CAP Foundation. Dr. Eric Glassy has also authored several publications in his fields of interest and has written and edited key textbooks in the field of pathology. Dr. Eric Glassy’s immunohistology work has confirmed and extended the specificity and comparability of the Pritumumab database.

Nascent Biotech’s Senior Management Team is honored to have Dr. Santosh Kesari and Dr. Eric Glassy as part of their Advisory board.

About Nascent Biotech, Inc.:

Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.

Safe Harbor:

Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on October 28, 2014, and future filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact Information:

Nascent Biotech, Inc.
Sean Carrick
President

772.713.0541
sean.carrick@nascentbiotech.com
www.nascentbiotech.com

Nascent Biotech Announces Orphan Drug Designation for Brain Cancer

/in , /by

San Diego, CA, April 9th, 2015 – Nascent Biotech, Inc., (OTC.NBIO) is pleased to announce that it has been granted Orphan Drug Designation from the Office of Orphan Products Development of the FDA (Click here for link) for its Pritumumab product for the treatment of brain cancer.  According to Industry statistics, there are approximately 8,000 new cases of domestic brain cancer annually with few viable treatment options.

Dr. Mark Glassy, Nascent Biotech’s Chief Science Officer, is very optimistic about the results shown in early non- clinical study data.  “Our data are comparable with the data generated in the earlier Japanese studies.  We anticipate that by modifying the dosing of the previous Japanese human clinical trials, during upcoming domestic human clinical trials, we have the potential to markedly improve response rates.”

About Nascent Biotech, Inc.:
Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers.  Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.

Safe Harbor:
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995.  Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results.  These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks.  Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on October 28, 2014, and future filings with the Securities and Exchange Commission.  The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact Information:

Nascent Biotech, Inc.
Sean Carrick
President
772.713.0541
sean.carrick@nascentbiotech.com
www.nascentbiotech.com

Nascent Biotech Announces $225,000 NIH Grant Award in Conjunction with Mapp Biopharmaceutical

/in , /by

San Diego, CA, February 26th, 2015 – Nascent Biotech, Inc. (OTC: NBIO) and Mapp Biopharmaceutical announced today they have been awarded a $225,000 Small Business Innovative Research (SBIR) grant, titled “Novel Immunotherapy for Brain Cancer,” to fund initial development of tobacco plants as an adjunct expression system for Nascent Biotech’s lead candidate biopharmaceutical, Pritumumab, a monoclonal antibody for the treatment of brain cancer.

This grant is a collaboration between Nascent Biotech and Mapp Biopharmaceutical, a technology leader in plant-based manufacturing of monoclonal antibodies.

Dr. Mark Glassy of Nascent says, “This grant will help accelerate the development and manufacturing of potentially life-saving antibody treatments for patients suffering from brain cancer.”  Adding, “We are extremely pleased to have Mapp as a partner, as they are evaluating the therapeutic benefits of this novel expression system in clinical trials.”

“Mapp is delighted to partner with Nascent Biotech in developing a very promising cancer therapy antibody.  The opportunity to make a cost effective treatment accessible to all emerging market countries,  is compelling” says Dr. Kevin Whaley, Mapp CEO.

About Nascent Biotech, Inc.:
Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers.  Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.

Safe Harbor:
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995.  Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results.  These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks.  Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on October 28, 2014, and future filings with the Securities and Exchange Commission.  The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact Information:

Nascent Biotech, Inc.
Sean Carrick
President
772.713.0541
sean.carrick@nascentbiotech.com
www.nascentbiotech.com

Nascent Biotech Inc. Raises $1.2 Million in Initial Funding

/in , /by

San Diego, CA, Nascent Biotech Inc (NBIO: OTC) announced today that it has recently closed a non-brokered private placement round for aggregate gross proceeds of $1.2Million.

Management raised funds and the use of Proceeds will be for developing antibodies used to treat cancer; including manufacturing, preparation for human clinical trials, general working capital and administration.

Sean Carrick, President of Nascent commented, “We were overwhelmed by the interest in our initial round. We chose to accept strategic money in this first round as we believe the right partners will prove to be more beneficial in the long run.”

About Nascent Biotech, Inc.
Nascent Biotech is building a portfolio of innovative therapeutic antibodies, poised at various stages of development, ranging from laboratory to the eve of clinical trials. Nascent Biotech is using and developing natural human antibodies and responses obtained from the innate natural human immune response as a drug discovery platform for identifying new antibodies and antigens for commercialization.

We encourage any interested parties to visit http://www.nascentbiotech.com/

Issued on behalf of the Board of Directors of Nascent Biotech Inc.

Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on October 28, 2014, and future filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contact:

Nascent Biotech, Inc.
Sean Carrick
President
772.713.0541
sean.carrick@nascentbiotech.com
www.nascentbiotech.com

Jin-En International Group Holding Co. Acquires Nascent Biologics and Changes Name to Nascent Biotech Inc.

/in /by

Ft Lauderdale FL July 29, 2014 – Jin-En International Group Holding Co. (“Jin-en” or “the Company”) (PINK.BB: JINZ), is pleased to announce the acquisition 100% of the outstanding shares of Nascent Biologics, a Nevada corporation (“NBI”). As part of the acquisition, the Company has agreed to change its name to Nascent Biotech Inc. and plans on applying to FINRA for a change in the ticker symbol. The acquisition is a change in control and Jin-En’s previous business operations has been assigned to certain shareholders of Jin-En in exchange for the return of certain shares of the Company’s previously issued shares.

NBI is a biotechnology company developing human Monoclonal Antibodies (mAb’s) for immunotherapy of cancer. “NBI has developed a monoclonal antibody with the potential to treat a broad spectrum of cancer types,” stated Mark Glassy, the new President and CEO of Jin-En. Glassy further states, ”Pritumumab recognizes a unique, target not being explored by other biotech companies and the therapy has been safely utilized in 249 human brain cancer patients in Japan. The Company will pursue malignant brain tumors as an initial indication”

About Nascent Biotech Inc.:

NBI is a biotechnology company developing human Monoclonal Antibodies (mAb’s) for immunotherapy of cancer. Its lead therapeutic candidate, Pritumumab, was the first human antibody ever developed to treat a cancer patient and has been validated in 249 patients in Japan. The company is now developing a new clinical protocol and Initial New Drug (IND) package for commencement of new clinical trials to be conducted in the United States under the guidance of the US Food and Drug Administration (FDA).

Safe Harbor:

This news release contains “forward-looking statements” as that term is defined in the United States Securities Act of 1933, as amended and the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements, including beliefs, plans, expectations or intentions regarding the future, and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors, such as the inherent uncertainties associated with new business opportunities and development stage companies. We assume no obligation to update the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that they will prove to be accurate.

Contact:

Nascent Biotech Inc

Lowell Holden, CFO

Phone: (612) 961-5656

Fax: (612) 486-7055

Web: www.nascentbiotech.com

Email: lowell.holden@nascentbiotech.com